Insiders who reported open-market trades in the last 12 months at the companies Howard W. Robin files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Jonathan Zalevsky - $974K in NKTR purchases and sales in the last 12 months
Mark Andrew Wilson - $34K in NKTR purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Howard W. Robin is a corporate insider, tracked as President & CEO, Director of NEKTAR THERAPEUTICS (NKTR). InsiderAlpha holds 15 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Howard W. Robin submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Howard W. Robin been buying or selling stock?
Recorded transactions: 0 open-market purchases and 25 open-market sales ($2.42M) across all tracked filings.
Howard W. Robin is President & CEO, Director of NEKTAR THERAPEUTICS (NKTR). 15 SEC Form 4 filings on record going back to 2024, most recently on 20 August 2026. Most recent open-market trade: sold $30K of NKTR on 20 August 2026. Lifetime open-market sales: $2.42M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Howard W. Robin.
InsiderAlpha's records for Howard W. Robin go back to 2024: 15 primary Form 4 filings, an average of 5.0 per year. 4 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
